Product/Composition:- | Terbinafine Tablets |
---|---|
Strength:- | 250 mg |
Form:- | Tablets |
Reference Brands:- | Lamisil(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Terbinafine inhibits fungal squalene epoxidase, disrupting ergosterol synthesis and damaging cell membranes. It effectively treats dermatophyte skin and nail infections, offering rapid relief, high efficacy, and convenient oral dosing. Its safety and targeted action make it a preferred choice for superficial fungal infections.
Terbinafine tablets are approved in the EU and US for treating dermatophyte skin and nail infections. In the EU, Novartis’s Lamisil is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on comprehensive clinical data, biosimilarity, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and submissions, visit PharmaTradz. We ensure smooth market access for terbinafine tablets, helping you meet European and American standards for safe, effective antifungal therapy.